OakChart

Invivyd Inc

IVVDHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.5993+0.0249 (4.33%)
2026-11-11 22:41 CET
Market cap
169.31 USD m
Revenue, TTM
58.37 USD m
Net income, TTM
-107.33 USD m
Free cash flow, TTM
-109.66 USD m
EPS diluted, TTM
-0.37
P/E
-
Compare

Price

IVVD against its 20, 50 and 200-day averages
2050200miss
0.501.001.5015.6M31.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IVVDclose 0.6020-day 0.6050-day 0.73200-day 1.100.6052w low

80.5% under the 52-week high of 3.07 on 17 Nov 2025. 52-week low 0.53 on 31 Jul 2026. Last 15 sessions, 23.2% high to low

Volume 0.33× normal · the line is the 50-bar volume average

Profile

IVVD
52-week range, 3% of the way up
0.533.07

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

IndexRUT
Employees122
IPOAug 06, 2021
Beta1.30
ATR, 14d0.06
Rel volume0.33
Short float13.84%
Insider own11.23%
Inst own78.35%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap176.65M
Enterprise Value24.96M
Income-107.33M
Sales58.37M
Book/sh0.61
Cash/sh0.54
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees122
IPOAug 06, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S3.03
P/B0.98
P/C1.10
P/FCF-
EV/EBITDA-
EV/Sales0.43
Quick Ratio5.86
Current Ratio5.87
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.37
EPS next Y-0.33
EPS next Q-0.13
EPS this Y-75.56%
EPS next Y37.97%
EPS next 5Y19.51%
EPS past 3/5Y48.48% 12.29%
Sales past 3/5Y- -
EPS Y/Y TTM59.47%
Sales Y/Y TTM26.30%
EPS Q/Q-13.34%
Sales Q/Q21.20%
EarningsAug 13 AMC
EPS/Sales Surpr.-31.21% -0.81%

Ownership

Insider Own11.23%
Insider Trans-0.68%
Inst Own78.35%
Inst Trans-4.94%
ROA-69.69%
ROE-95.89%
ROIC-57.14%
Gross Margin88.78%
Oper. Margin-192.81%
Profit Margin-183.90%
SMA20-0.86%
SMA50-18.03%
SMA200-45.49%
Trades-

Technical

Shs Outstand294.76M
Shs Float261.67M
Short Float13.84%
Short Ratio7.00
Short Interest36.20M
52W High3.07 -80.48%
52W Low0.53 13.57%
Volatility9.72% 9.18%
ATR (14)0.06
RSI (14)44.19
Beta1.30
Rel Volume0.33
Avg Volume5.17M
Volume1,719,192

Performance

Perf Week-5.41%
Perf Month-7.23%
Perf Quarter-12.60%
Perf Half Y-59.23%
Perf YTD-75.74%
Perf Year-63.68%
Perf 3Y-57.19%
Perf 5Y-96.88%
Perf 10Y-
Recom1.00
Target Price10.00
Prev Close0.57
Price0.60
Change %4.33%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Dec 22, 2025InitiatedBBTIG ResearchBuy$10+1,568.6%
Nov 25, 2025DowngradeDD. Boral CapitalBuy → Hold
Oct 06, 2025InitiatedCCantor FitzgeraldOverweight$10+1,568.6%
Apr 05, 2024UpgradeGGuggenheimNeutral → Buy$9+1,401.8%
Mar 26, 2024UpgradeMMorgan StanleyEqual-Weight → Overweight$4 → $10+1,568.6%
Dec 19, 2023UpgradeMMorgan StanleyUnderweight → Equal-Weight$1 → $4+567.4%
May 01, 2023InitiatedHH.C. WainwrightBuy$5+734.3%

Peers

Mkt cap
TickerCompanyMkt cap
VIRVir Biotechnology Inc2.25B
ARCTArcturus Therapeutics Holdings Inc268.33M
NVAXNovavax Inc1.65B
VALNValneva SE ADR563.17M
SABSSAB Biotherapeutics Inc280.17M
INOInovio Pharmaceuticals Inc152.51M
ADMAAdma Biologics Inc2.93B
GOVXGeovax Labs Inc1.10M
NNVCNanoViricides Inc35.23M
AIMAIM ImmunoTech Inc5.93M

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lee Timothy EdwardChief Commercial OfficerAug 17 '26Sale0.7222,35516,140197,362Aug 18 08:10 PM
Lee Timothy EdwardChief Commercial OfficerAug 18 '26Sale0.8418,42515,530178,937Aug 18 08:10 PM
Green JulieChief Human Resources OfficerAug 17 '26Sale0.7222,35516,140187,362Aug 18 08:10 PM
Green JulieChief Human Resources OfficerAug 18 '26Sale0.8418,42515,530168,937Aug 18 08:10 PM
Duke William E.Chief Financial OfficerAug 17 '26Sale0.7222,35516,140187,362Aug 18 08:10 PM
Duke William E.Chief Financial OfficerAug 18 '26Sale0.8418,42515,530168,937Aug 18 08:10 PM
Andersen JillChief Legal Officer, SecretaryAug 17 '26Sale0.7237,25626,899314,480Aug 18 08:10 PM
Andersen JillChief Legal Officer, SecretaryAug 18 '26Sale0.8430,70625,882283,774Aug 18 08:10 PM
Allen Robert D. IIIChief Scientific OfficerAug 17 '26Sale0.7220,67914,930195,808Aug 18 08:10 PM
Allen Robert D. IIIChief Scientific OfficerAug 18 '26Sale0.8417,04314,366178,765Aug 18 08:10 PM
Lee Timothy EdwardOfficerAug 17 '26Proposed Sale0.7240,80029,413Aug 17 04:06 PM
Green JulieOfficerAug 17 '26Proposed Sale0.7240,80029,413Aug 17 04:05 PM
Duke William E.OfficerAug 17 '26Proposed Sale0.7240,80029,413Aug 17 04:05 PM
Andersen JillOfficerAug 17 '26Proposed Sale0.7268,00149,022Aug 17 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.140-0.107-0.14014.2914.403
2026Q12026-05-14-0.130-0.073-0.13413.7418.043
2025Q42026-03-050.020-0.083-0.03917.2017.204
2025Q32025-11-06-0.060-0.080-0.06213.1313.103
2025Q22025-08-14-0.120-0.004-0.12211.7925.992
2025Q12025-05-15-0.140-0.030-0.13611.3034.453
2024Q42025-03-20-0.150-0.200-0.15413.8013.573
2024Q32024-11-14-0.510-0.338-0.5089.3027.254
2024Q22024-08-14-0.400-0.373-0.3962.265.003
2024Q12024-05-09-0.380-0.467-0.3760.000.003
2023Q42024-03-28-0.670-0.435-0.6710.000.004
2023Q32023-11-09-0.360-0.505-0.3590.000.004
2023Q22023-08-10-0.460-0.370-0.4590.000.004
2023Q12023-05-11-0.320-0.345-0.3250.000.004
2022Q42023-03-23-0.410-0.360-0.4090.000.003
2022Q32022-11-10-0.420-0.443-0.4160.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-5.320-2.313-2.0470.000.00
2022FY-2.230-2.185-2.2290.000.00
2023FY-1.810-1.523-1.8140.000.00
2024FY-1.430-1.390-1.43325.3825.15
2025FY-0.300-0.391-0.30053.4351.72
2026FY--0.527--60.05
2027FY--0.327--86.98
2028FY--0.157--230.09
2029FY-0.443--482.35
2030FY-0.745--799.9

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-3130015.0414.6015.90
2026Q3S2026-10-2830115.0414.6015.90
2026Q3S2026-09-2831215.0314.5915.90
2026Q3S2026-08-1731215.0414.6015.90
2026Q3S2026-08-1431116.4714.6020.20
2026Q3S2026-08-1330017.0213.1520.20
2026Q3S2026-08-0130017.0213.1520.20
2026Q3S2026-05-1930117.0213.1520.20
2026Q3S2026-05-1831117.0213.1520.20
2026Q3S2026-05-1531017.6413.1522.06
2026Q3S2026-05-1421019.8817.7022.06
2026Q3S2026-04-2321019.8817.7022.06
2026Q3S2026-04-0931120.5917.7022.06
2026Q3S2026-04-0831120.6017.7022.10

Estimate history

EPS, annual-0.587-2.047-2.229-1.814-1.433-0.305-0.373
Period202020212022202320242025TTM
EPS, quarterly-0.396-0.508-0.154-0.136-0.122-0.062-0.039-0.134-0.139
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000025.38453.42658.37
Period202020212022202320242025TTM
Sales, quarterly2.2649.313.8211.30411.78613.12917.20713.74414.285
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual111.246110.783109.044110.161119.835281.987294.755
Period202020212022202320242025MRQ
Shares, quarterly119.443119.604119.835119.961120.143214.409281.987282.804294.755
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue58.3753.4325.380.000.000.000.00
Cost of Goods Sold Incl. D&A6.555.854.732.030.460.000.00
Gross Profit51.8147.5720.65-2.03-0.46-0.000.00
Selling, General and Administrative Excl. Other164.35103.13197.53205.75225.80219.4165.33
Research and Development78.1938.31137.25158.66179.21182.8962.12
Other Operating Expense0.000.000.000.0017.370.000.00
Operating Income-112.53-55.56-176.88-207.78-243.63-219.41-65.33
Interest Expense0.000.000.000.000.000.000.00
Unusual Expense0.000.000.004.974.407.500.00
Net Income Before Taxes-107.33-52.49-169.93-198.64-241.32-226.79-65.32
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-107.33-52.49-169.93-198.64-241.32-226.79-65.32
Net Income From Continuing Operations-107.33-52.49-169.93-198.64-241.32-226.79-65.32
Net Income-107.33-52.49-169.93-198.64-241.32-226.79-65.32
EPS (Recurring)-0.33-0.30-1.43-1.78-2.20-2.00-0.59
EPS (Basic, Before Extraordinaries)-0.37-0.30-1.43-1.81-2.23-2.05-0.59
EPS (Diluted)-0.37-0.30-1.43-1.81-2.23-2.05-0.59
EBITDA-110.52-53.45-173.76-205.75-243.17-219.41-65.33
Non-Operating Income (Expense)5.203.076.9514.126.710.120.01
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense11.2311.6419.7918.6821.6517.760.15
Price To Sales Ratio4.797.962.07----
Gross Margin88.7889.0481.36----
Operating Margin-192.81-103.99-696.80----
Net Margin-183.90-98.25-669.42----
Shares Outstanding294.76281.99119.84110.16109.04110.78111.25
Market Capitalization169.31169.3153.00433.85163.47807.69875.55

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue14.2913.7417.2113.1311.7911.3013.829.30
Cost of Goods Sold Incl. D&A1.911.541.571.521.191.572.241.36
Gross Profit12.3712.2015.6311.6110.609.7311.587.93
Selling, General and Administrative Excl. Other58.1955.3428.1922.6325.6626.6530.8170.25
Research and Development29.3730.7310.058.059.5710.6417.9157.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-45.82-43.14-12.55-11.02-15.06-16.92-19.23-62.31
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-44.39-41.40-11.07-10.47-14.66-16.29-18.44-60.74
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-44.39-41.40-11.07-10.47-14.66-16.29-18.44-60.74
Net Income From Continuing Operations-44.39-41.40-11.07-10.47-14.66-16.29-18.44-60.74
Net Income-44.39-41.40-11.07-10.47-14.66-16.29-18.44-60.74
EPS (Recurring)-0.14-0.13-0.04-0.06-0.12-0.14-0.15-0.51
EPS (Basic, Before Extraordinaries)-0.14-0.13-0.04-0.06-0.12-0.14-0.15-0.51
EPS (Diluted)-0.14-0.13-0.04-0.06-0.12-0.14-0.15-0.51
EBITDA-45.18-42.62-12.12-10.59-14.56-16.18-17.71-61.75
Non-Operating Income (Expense)1.431.741.490.550.400.630.791.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.902.702.563.073.182.833.062.87
Price To Sales Ratio4.797.2113.043.741.861.982.0910.54
Gross Margin86.6288.7690.8588.4389.9286.0983.7985.32
Operating Margin-320.76-313.85-72.96-83.96-127.78-149.70-139.14-670.01
Net Margin-310.77-301.22-64.33-79.75-124.38-144.10-133.45-653.11
Shares Outstanding294.76282.80281.99214.41120.14119.96119.84119.60
Market Capitalization169.31367.37684.49214.4585.7772.6153.00121.83

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments226.6969.35200.64371.99591.42114.99
Short Term Receivables14.6011.170.930.380.000.00
Inventories0.260.000.000.000.000.00
Other Current Assets5.9220.1623.314.5525.292.39
Total Current Assets247.47100.68224.88376.92616.71117.38
Net Property, Plant & Equipment3.812.894.126.060.080.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets-----0.00
Other Assets25.6125.940.170.193.300.00
Total Assets276.88129.51229.18383.17620.09117.38
Short Term Debt Incl. Current Port. of LT Debt1.311.301.441.560.000.00
Accounts Payable13.7410.457.951.525.780.00
Other Current Liabilities19.1150.2240.9021.9556.2813.07
Total Current Liabilities34.1661.9850.2925.0362.0613.07
Long Term Debt1.180.000.722.170.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.700.000.010.01
Total Liabilities35.3461.9851.7127.2062.0713.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00169.55
Common Equity241.5467.54177.47355.97558.02-65.25
Total Shareholders Equity241.5467.54177.47355.97558.02104.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity241.5467.54177.47355.97558.02104.30
Total Liabilities & Stockholders Equity276.88129.51229.18383.17620.09117.38
Book Value Per Share0.860.561.613.265.04-0.59
Tangible Book Value Per Share0.860.561.613.265.04-0.59
Full-Time Employees12299948410374
Price to Book Ratio0.940.641.760.431.441.38
Return on Assets-25.83-94.75-64.88-48.11-61.50-
Return on Equity-33.96-138.71-74.48-52.81-68.48-
Return on Invested Capital-21.63-251.60-111.48-67.38-40.64-62.63
Quick Ratio7.241.624.4715.069.948.98
Current Ratio7.241.624.4715.069.948.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-107.33-52.49-169.93-198.64-241.32-226.79-65.32
Depreciation2.022.113.112.030.460.00-
Other Funds (Non Cash)11.4411.9419.7917.5637.0019.2640.07
Funds from Operations-93.87-38.44-147.02-179.05-203.86-207.53-25.25
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-14.55-19.69-23.475.89-16.1322.7910.68
Cash from Operating Activities-108.42-58.13-170.49-173.16-219.99-184.74-14.57
Capital Expenditures-1.24-0.15-0.14-0.61-1.71-0.080.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.00281.30-228.96-50.630.00
Purchase of Investments0.000.000.00-91.20-297.96-188.630.00
Sale Or Maturity of Investments0.000.000.00372.5069.00138.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-1.24-0.15-0.14280.68-230.67-50.710.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock234.83215.6339.331.040.51662.68129.56
Repurchase of Common Pref Stock0.000.000.00-0.00-0.000.00-0.00
Sale of Common Pref Stock234.83215.6339.331.050.51662.68129.56
Proceedsfrom Stock Options234.05214.9738.69-0.150.00662.680.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities234.83215.6339.331.040.51662.68129.56
Exchange Rate Effect-0.000.01----
Net Change in Cash125.17157.34-131.29108.56-450.15427.24114.99
Free Cash Flow-109.66-58.29-170.63-173.78-221.69-184.82-14.57
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments160.08184.15226.6984.9734.9148.08
Short Term Receivables11.6812.2114.6010.138.818.75
Inventories0.310.260.260.430.430.44
Other Current Assets10.048.295.9214.2415.1318.55
Total Current Assets182.11204.91247.47109.7759.2875.83
Net Property, Plant & Equipment10.2510.223.813.994.402.48
Total Investments and Advances0.000.000.000.000.000.00
Other Assets26.5226.6125.6125.4025.4525.44
Total Assets218.88241.74276.88139.1689.14103.74
Short Term Debt Incl. Current Port. of LT Debt1.621.591.311.081.070.89
Accounts Payable9.492.0213.7418.1018.058.74
Other Current Liabilities19.9328.0419.1125.3125.3339.96
Total Current Liabilities31.0331.6634.1644.5044.4549.59
Long Term Debt6.787.031.181.591.900.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities37.8038.6935.3446.0946.3549.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity181.08203.05241.5493.0742.7954.15
Total Shareholders Equity181.08203.05241.5493.0742.7954.15
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity181.08203.05241.5493.0742.7954.15
Total Liabilities & Stockholders Equity218.88241.74276.88139.1689.14103.74
Book Value Per Share0.610.720.860.430.360.45
Tangible Book Value Per Share0.610.720.860.430.360.45
Full-Time Employees--122---
Price to Book Ratio0.941.525.693.091.581.07
Return on Assets-69.69-44.92-25.83-39.76-82.65-89.42
Return on Equity-95.89-60.34-33.96-67.94-120.08-122.69
Return on Invested Capital-23.63-19.71-4.56-11.06-32.81-30.08
Quick Ratio5.866.467.242.461.321.52
Current Ratio5.876.477.242.471.331.53

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-44.39-41.40-11.07-10.47-14.66-16.29
Depreciation0.640.510.430.430.500.74
Other Funds (Non Cash)2.852.752.573.283.272.83
Funds from Operations-40.91-38.14-8.07-6.76-10.89-12.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.10-3.58-7.39-1.49-2.42-8.40
Cash from Operating Activities-43.01-41.71-15.46-8.25-13.30-21.13
Capital Expenditures-0.51-0.730.000.00-0.01-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.51-0.730.000.00-0.01-0.14
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock19.44-0.10157.1858.310.130.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock19.44-0.10157.1858.310.130.01
Proceedsfrom Stock Options19.30-0.31156.7958.26-0.01-0.07
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities19.44-0.10157.1858.310.130.01
Exchange Rate Effect------0.01
Net Change in Cash-24.07-42.54141.7250.06-13.17-21.27
Free Cash Flow-43.52-42.44-15.46-8.25-13.31-21.27

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 25.38M 2025: 53.43M
United States2024: 25.38M 2025: 53.43M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.84%36.2M261.7M5.05M
2026-10-1514.16%37.0M261.7M4.96M
2026-09-3012.94%33.9M261.7M4.65M
2026-09-1511.68%30.6M261.7M4.27M
2026-08-3111.38%29.8M261.7M4.58M
2026-08-1412.46%30.9M248.2M4.39M
2026-07-3111.13%27.8M249.9M4.42M
2026-07-1511.73%29.3M249.9M4.11M
2026-06-3010.44%27.4M262.9M4.39M
2026-06-1513.10%34.4M262.9M3.64M
2026-05-2913.21%30.9M234.1M3.05M
2026-05-1513.27%31.1M234.1M2.82M
2026-04-3013.02%29.3M224.7M2.82M
2026-04-1513.02%29.3M224.7M3.18M
2026-03-3111.79%26.5M224.5M2.84M
2026-03-1310.92%24.5M224.5M3.32M
2026-02-2710.09%22.7M224.5M3.60M
2026-02-1310.31%22.7M220.2M6.70M
2026-01-309.88%22.3M225.9M6.61M
2026-01-159.48%21.4M225.9M6.85M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.100.200.154.5232,8700.000.722-0.0080.000
call1.000.000.050.055.2761,8680.000.419-0.0110.000
call1.500.000.050.055.2843730.000.247-0.0080.000
call2.000.001.000.106.21115.000.000.223-0.0100.000
call2.500.002.950.056.86550.000.000.212-0.0110.000
call5.000.002.950.008.7020.000.000.187-0.0120.000
call7.500.000.050.059.4021.000.000.184-0.0120.000
put0.500.000.300.1011.63723.005.00-0.157-0.0150.000
put1.000.000.650.669.4461400.00-0.708-0.0070.000
put1.500.401.400.8517.96610.000.00-0.757-0.0090.000
put2.000.901.901.4525.7244.000.00-0.777-0.0100.000
put2.500.603.900.000.0000.000.00-0.788-0.0100.000
put5.003.106.400.000.0000.000.00-0.813-0.0120.000
put7.505.608.900.000.0000.000.00-0.822-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-298-KCurrent report2026-09-29SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-023Initial statement of beneficial ownership of securities2026-08-30SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-30SEC
2026-09-018-KCurrent report2026-08-30SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-043Initial statement of beneficial ownership of securities2026-07-31SEC
2026-07-28SCHEDULE 13GSEC
2026-07-248-KCurrent report2026-07-23SEC
2026-07-068-KCurrent report2026-07-06SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800177.09K10
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0200354.23K10
2026-010000
2025-120000
2025-11125.00K100

Institutional holders

Manager% owned
Jupiter Topco LLC11.60%
BVF INC/IL9.56%
MAVERICK CAPITAL LTD6.44%
PERCEPTIVE ADVISORS LLC6.28%
BlackRock, Inc.5.48%
VANGUARD CAPITAL MANAGEMENT LLC3.56%
M28 Capital Management LP3.14%
Saturn V Capital Management LP2.85%
Soleus Capital Management, L.P.2.62%
Point72 Asset Management, L.P.2.56%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.64%
iShares Russell 2000 ETF1.82%
VANGUARD EXTENDED MARKET INDEX FUND0.81%
Fidelity Small Cap Index Fund0.78%
iShares Russell 2000 Value ETF0.69%
VANGUARD RUSSELL 2000 INDEX FUND0.41%
Fidelity Extended Market Index Fund0.26%
iShares Micro-Cap ETF0.24%
iShares Core S&P Total U.S. Stock Market ETF0.20%
Schwab Small-Cap Index Fund0.18%

OakChart. IVVD. Cached 15 minutes.